Literature DB >> 388310

The Basel experience with total body irradiation for conditioning patients with acute leukemia for allogeneic bone marrow transplantation.

B Speck, P Cornu, C Nissen, A Gratwohl, J Sartorius.   

Abstract

We are reporting our experience with 13 patients suffering from end stage acute leukemia that were prepared for allogeneic bone marrow transplantation by combined chemotherapy followed by high dose cyclophosphamide (Cy) and total body irradiation (TBI). Only one patient became a long term survivor. Of the evaluable 12 patients, 6 died of interstitial pneumonia, 4 of GvH and 1 of recurrent leukemia. We conclude that adding combined chemotherapy to the standard conditioning program with Cy and TBI probably increases the risk of developing fatal interstitial pneumonia without eliminating the risk of recurrent leukemia. We suggest that allogenic marrow grafts should be performed earlier in the course of refractory acute leukemias, because in patients with end stage disease its chances of being curative are small.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 388310

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  2 in total

1.  Higher Reported Lung Dose Received During Total Body Irradiation for Allogeneic Hematopoietic Stem Cell Transplantation in Children With Acute Lymphoblastic Leukemia Is Associated With Inferior Survival: A Report from the Children's Oncology Group.

Authors:  Natia Esiashvili; Xiaomin Lu; Ken Ulin; Fran Laurie; Sandy Kessel; John A Kalapurakal; Thomas E Merchant; David S Followill; Vythialinga Sathiaseelan; Mary K Schmitter; Meenakshi Devidas; Yichen Chen; Donna A Wall; Patrick A Brown; Stephen P Hunger; Stephan A Grupp; Michael A Pulsipher
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-02-23       Impact factor: 7.038

Review 2.  Pulmonary Toxicity After Total Body Irradiation - Critical Review of the Literature and Recommendations for Toxicity Reporting.

Authors:  Jennifer Vogel; Susanta Hui; Chia-Ho Hua; Kathryn Dusenbery; Premavarthy Rassiah; John Kalapurakal; Louis Constine; Natia Esiashvili
Journal:  Front Oncol       Date:  2021-08-26       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.